SENS Jan 2023 1.000 call
| Previous close | 1.8400 |
| Open | 2.2000 |
| Bid | 0.6900 |
| Ask | 2.1700 |
| Strike | 1.00 |
| Expiry date | 2023-01-20 |
| Day's range | 1.9300 - 2.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.51k |
- Business Wire
Senseonics Announces CE Mark Approval of the Eversense E3 Continuous Glucose Monitoring System
GERMANTOWN, Md., June 16, 2022--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has received CE Mark approval for the next-generation Eversense® E3 CGM System, the longest-lasting system available, with exceptional accuracy. The CE Mark approval confirms that the Eversense E3 meets the requirements of the
- Business Wire
Senseonics to Participate in the Jefferies Healthcare Conference
GERMANTOWN, Md., May 26, 2022--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY.
- Business Wire
Senseonics to Participate in the H.C. Wainwright Global Investment Conference
GERMANTOWN, Md., May 16, 2022--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming hybrid H.C. Wainwright Global Investment Conference.
